anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Efficacy and safety data of LUCENTIS are derived from studies D-1 and D-2 (See Section 14.4 Diabetic Retinopathy below). All enrolled patients had DR and DME at baseline.

The safety and efficacy of LUCENTIS were assessed in two randomized, double-masked, 3-year studies. The studies were sham-controlled through Month 24. Patient age ranged from 21 to 91 years, with a mean age of 62 years. A total of 759 patients (LUCENTIS 0.3 mg, 250 patients; LUCENTIS 0.5 mg, 252 patients; sham, 257 patients) were enrolled, with 582 (77%) completing through Month 36.

In Studies D-1 and D-2, patients received monthly LUCENTIS 0.3 mg or 0.5 mg intravitreal injections or monthly sham injections during the 24-month controlled treatment period. From Months 25 through 36, patients who previously received sham were eligible to receive monthly LUCENTIS 0.5 mg and patients originally randomized to monthly LUCENTIS 0.3 mg or 0.5 mg continued to receive their assigned dose. All patients were eligible for macular focal/grid laser treatment beginning at Month 3 of the 24-month treatment period or panretinal photocoagulation (PRP) as needed. Through Month 24, macular focal/grid laser treatment was administered in 94 of 250 (38%) patients treated with LUCENTIS 0.3 mg and 185 of 257 (72%) patients treated with sham; PRP was administered in 2 of 250 (1%) patients treated with LUCENTIS 0.3 mg and 30 of 257 (12%) patients treated with sham.

Compared to monthly LUCENTIS 0.3 mg, no additional benefit was observed with monthly treatment with LUCENTIS 0.5 mg. At Month 24, after monthly treatment with LUCENTIS 0.3 mg, the following clinical results were observed:

Visual acuity outcomes observed at Month 24 in patients treated with LUCENTIS 0.3 mg were maintained with continued treatment through Month 36 in both DME studies. Patients in the sham arms who received LUCENTIS 0.5 mg beginning at Month 25 achieved lesser VA gains compared to patients who began treatment with LUCENTIS at the beginning of the studies.

In Studies D-1 and D-2, patients received monthly injections of LUCENTIS for 12 or 36 months, after which 500 patients opted to continue in the long-term follow-up study. Of 298 patients who had at least 12 months of follow-up from Month 36, 58 (19.5%) patients maintained vision with no further therapy. The remaining 202 patients were followed for less than 12 months.
The invention provides application of lactobacillus plantarum fermented sijunzi decoction in nonalcoholic steatohepatitis. In vitro orthogonal experimental results show that the codonopsis pilosula: licorice root: white atractylodes rhizome: the mixture of Poria solution has optimal antioxidant activity by Lactobacillus plantarum fermentation broth. Animal experiments show that alanine aminotransferase and malondialdehyde in the liver homogenate of the mice in the model group are obviously increased compared with those in the blank group. The MDA and triglyceride of the lactobacillus plantarum treatment group, the Sijunzi decoction and the combined fermentation group are all remarkably reduced; ALT and cholesterol were significantly reduced in SJZT group. The pathological structure of the liver tissue shows that the steatosis of the liver cells in the treatment group is obviously relieved, the infiltration of inflammatory cells is reduced, and the outline of the lobular structure of the liver is restored. The liver index and spleen index of the SJZT + P group are also obviously reduced. The lactobacillus plantarum fermented sijunzi decoction can effectively improve the hepatic steatosis and damage of NASH; the mechanism is related to miR-124-3p/ELF-3 targeted regulation.
As soon as possible after hospital admittance the patients will have their headrest positioned at 35 degrees straight elevation of backrest in Semi-Fowler's position (elevated lower limp position). This position will be maintained during the initial 72 hours or until extubated. Adherence to assigned stratum will be checked every 8 hours and cuff pressure will be assessed and corrected if needed at the same time during the intervention period. The backrest position intervention may be temporarily canceled by the treating physician if needed for procedures or mobilization but will return to the assigned position if invasive ventilator treatment with orotracheal intubation is continued. The intervention will be terminated if the patient is extubated, or a tracheostomy is performed, during the intervention period of 72 hours.
Cerebral cavernous angioma (CA) is a capillary microangiopathy affecting more than a million Americans, predisposing them to a premature risk of brain hemorrhage. Fewer than 200,000 cases who have suffered a recent symptomatic hemorrhage (SH) are most likely to re-bleed again with serious clinical sequelae, and are the primary focus of therapeutic development. Genetic mechanisms of CA have been extensively studied, and consequent signaling aberrations in the neurovascular unit. These include proliferative dysangiogenesis, blood-brain barrier hyperpermeability, inflammation and immune mediated processes, anticoagulant vascular domain, and gut microbiome-driven mechanisms. Plasma levels of molecules reflecting these mechanisms and measures of vascular permeability and hemorrhage leak on magnetic resonance imaging (MRI) have been correlated with CA hemorrhage in pilot studies. It would be desirable to optimize these biomarkers to accurately diagnose CASH, to prognosticate the risk of future SH, and to monitor cases after a bleed and in response to therapy. This would influence clinical management, and select higher risk cases for clinical trials. Additional candidate biomarkers are emerging from ongoing mechanistic and differential transcriptome studies, which would be expected to further enhance the sensitivity and specificity of diagnosis and prediction of CASH. Weighed combinations of levels of plasma proteins and characteristic micro-ribonucleic acids (miRNA) may further strengthen biomarker associations. Plasma biomarkers may reflect (and potentially replace) more cumbersome and expensive imaging biomarkers for monitoring CA hemorrhage. We here assemble CA researchers and propose to deploy advanced statistical and computational biology approaches for the integration of novel candidate biomarkers. In Specific Aim 1 we assess these biomarkers in a large CA cohort to discover the best plasma biomarkers and validate them in sex, age and relevant clinical subgroups. In Specific Aim 2 we compare changes in MRI measures of vascular permeability and hemorrhage with plasma biomarkers over time. In Specific Aim 3 we query the biomarkers in non-CA subjects, to identify potential confounders in the clinical context. This project integrates analytic and computational biology expertise to develop blood tests for better CASH diagnosis and prognosis. The project tests a novel integrational approach of biomarker development in a mechanistically defined cerebrovascular disease with a relevant context of use. This approach is applicable to other neurological diseases with similar pathobiologic features.
Overdosage reports with alprazolam are limited. As in all cases of drug overdosage, respiration, pulse rate, and blood pressure should be monitored. General supportive measures should be employed, along with immediate gastric lavage. Intravenous fluids should be administered and an adequate airway maintained. If hypotension occurs, it may be combated by the use of vasopressors. Dialysis is of limited value. As with the management of intentional overdosing with any drug, it should be borne in mind that multiple agents may have been ingested.

Flumazenil, a specific benzodiazepine receptor antagonist, is indicated for the complete or partial reversal of the sedative effects of benzodiazepines and may be used in situations when an overdose with a benzodiazepine is known or suspected. Prior to the administration of flumazenil, necessary measures should be instituted to secure airway, ventilation and intravenous access. Flumazenil is intended as an adjunct to, not as a substitute for, proper management of benzodiazepine overdose. Patients treated with flumazenil should be monitored for re-sedation, respiratory depression, and other residual benzodiazepine effects for an appropriate period after treatment. The prescriber should be aware of a risk of seizure in association with flumazenil treatment, particularly in long-term benzodiazepine users and in cyclic antidepressant overdose. The complete flumazenil package insert including CONTRAINDICATIONS, WARNINGS and PRECAUTIONS should be consulted prior to use.
Participant Introduction Form, Cyber Sexual Violence Scale, Sensitivity Scale for Cyber Bullying (SZBÖ) Young Adult Form, Ensuring Personal Cyber Security Scale will be applied to the control group of kindergarten teaching female students as a pre-test. The Participant Introduction Form, Cyber Sexual Violence Scale, Sensitivity Scale for Cyber Bullying (SZSS) Young Adult Form, and Ensuring Personal Cyber Security Scale will be applied to the control group again after an average of 8-10 weeks without any intervention. In accordance with ethical principles, after the final results of the control group are collected, the videos in the training content will be sent to the control group.
The invention relates to a traditional Chinese medicine preparation for treating hypertension, which is prepared from the following raw materials: ramulus Uncariae cum uncis, Concha Haliotidis, rhizoma Gastrodiae, Eucommiae cortex, fructus Gardeniae, Saviae Miltiorrhizae radix, folium et ramulus Clerodendri Trichotomi, Polygoni Multiflori radix, rhizoma Pinelliae, etc. 17 Chinese medicinal materials, and can be made into various dosage forms for oral administration according to different requirements of patients. Hypertension is a clinical syndrome with elevated arterial blood pressure as the main component. The traditional Chinese medicine considers that the hypertension belongs to the categories of vertigo, headache and the like. At present, hypertension can not be cured radically, and most patients need to take antihypertensive drugs for life. However, the patient with hypertension finally dies due to acute cerebrovascular disease by losing the response to the existing hypotensive drugs. Survivors, of which over 75% remain with varying degrees of disability. The invention can effectively treat hypertension, the cure rate is more than 95%, the effective rate is 100%, and the biggest advantage is that the treatment time is short, long-term administration is not needed, and the disease does not rebound once cured.
A family of polyfunctional surface-active comonomers which act to improve the adhesion between a resin or composite material and solid surfaces capable of binding polyvalent cations is described. These polyfunctional surface-active comonomers, or "PolySACs", are preferably the reaction product of an epoxy acrylate or methacrylate and an aminobenzoate. The adhesion of the resin or composite material to certain solid surfaces is also improved by the preparatory treatment of these surfaces with a monobasic acid of intermediate strength followed by treatment with a mordant. In its most preferred form the invention is employed in reconstructive dental work to improve the adhesion between a resin or composite material and dentin. The dentin is cleansed with isotonic formic acid, treated with an isotonic ferric chloride mordant and then treated with a PolySAC which is the reaction product of an oligomeric diglycidyl ether, acrylic acid and lithium ortho-aminobenzoate. The resin or composite material is then applied.
The invention discloses chilblain treatment fluid. The chilblain treatment fluid comprises: by mass, 100 parts of water, 20 to 30 parts of free-range cock oil, 30 to 40 parts of refined salt, and 0.8 to 1.2 parts of ginseng. A production method of the chilblain treatment fluid comprises the following steps of 1, treating the free-range cock oil, 2, treating the refined salt, 3, treating the water, 4, preparing the treated free-range cock oil, 5, treating the ginseng, and 6, mixing well the solution obtained by the step 4 and the ginseng solution obtained by the step 5 to obtain the chilblain treatment fluid. The chilblain treatment fluid adopts free-range cock oil as a main material and thus having the advantages of convenient acquirement of raw material, low price and good effects of treatment of chilblain. After the chilblain treatment fluid is utilized for 3 to 7 days, various chilblain symptoms of redness, swelling, ache, itch and the like can be removed and reappear difficultly. In production of the chilblain treatment fluid, the various raw materials are subjected to high-temperature sterilization and low-temperature disinfection so that the safety of the raw materials is guaranteed. Because chilblain treatment fluid can penetrate into the skin, the safety of raw materials and products is important especially.
PURPOSE:To obtain a biologically active polypeptide consisting of a specific amino acid consequence, stable, having high specific activity, low side effects and broad reaction spectrum range and useful in anticancer agent, etc. CONSTITUTION:The desired and appointed codon of constitutive amino acid of human tumor necrosis (TNF) protein is selected and chemically synthesized to provide a human TNF gene (A). Then a terminator is provided to the gene (A) to prepare an expression type A gene, which is cloned into a vector derived from pBR322 to afford an expression type plasmid (B) (e.g. pTNF401A) of the A gene. Then the B plasmid is subjected to treatment by restriction enzyme to give a recombinant plasmid (e.g. pTNF471) (C) containing DNA domain coding a biologically (antitumor) active polypeptide having amino acid conse quence such as amino acid, etc., expressed by the formula or the polypeptide with which Met (L-methionine) is combined at the amino end of the polypeptide. Then Escherichia coli, etc., is transformed with the C plasmid and the resultant recombinant cell is cultivated in a culture medium and a biologically active polypeptide produced and accumulated in the culture medium is separated.
Renal ischemia-reperfusion injury (IRI) is a common disease with high morbidity and mortality. Renal IRI can cause the disorder of immune microenvironment and reprograming the immune microenvironment to alleviate excessive inflammatory response is crucial for its treatment. Cytokine IL-33 can improve the immune inflammatory microenvironment by modulating both innate and adaptive immune cells, and serve as an important target for modulating immune microenvironment of renal IRI. Herein, we report that bilobetin-functionalized ultrasmall Cu2- xSe nanoparticles (i.e., CSPB NPs) can activate the PKA/p-CREB/IL-33/ST2 signaling pathway to regulate innate and adaptive immune cells for reprograming the immune microenvironment of IRI-induced acute kidney injury. The biocompatible CSPB NPs can promote the polarization of M1-like macrophages into M2-like macrophages, and the expansion of ILC2 and Treg cells by activating IL-33/ST2 to modulate the excessive immune inflammatory response of renal IRI. More importantly, they can rapidly accumulate at the injured kidney to significantly alleviate IRI. This work demonstrates that modulating the expression of cytokines to reprogram immune microenvironment has great potential in the treatment of renal IRI and other ischemic diseases.
This study is a phase I/II, prospective, randomized, open-label trial designed to determine the effect size of change in GMFM-66 score in subjects treated with hCT-MSC or allogeneic CB and assess the safety of repeated doses of hCT-MSC in children with cerebral palsy. Children ages 2-5 years with cerebral palsy due to hypoxic ischemic encephalopathy, stroke, or periventricular leukomalacia may be eligible to participate. All participants will ultimately be treated with an allogeneic cell product at some point during the study. Participants will be randomized to one of three arms: (1) the "AlloCB" arm will receive one allogeneic CB infusion at the baseline visit; (2) the "MSC" arm will receive three hCT-MSC infusions, one each at baseline, three months, and six months; (3) the "natural history" arm will not receive an infusion at baseline but will receive an allogeneic CB infusion at 12 months. Motor outcome measures will be assessed at baseline, six-months, and one-year time points. Safety will be evaluated at each infusion visit and remotely for an additional 12 months after the final visit. Duration of study participation will be 24 months from the time of baseline visit. Randomization to treatment arms will be stratified by GMFCS level at study entry and etiology of CP (Stroke vs. Other).
The method involves setting and entering childcare or care plan in a central computer. The childcare or care plan is provided in the form of due care or nursing services by central computer to a user through a computer network. The client in an input device is identified. To-be provided care or nursing services with respect to input device customized for client is viewed. A specific data is transmitted to staff on terminal after acknowledging care or nursing service by staff, so that staff for each client is able to call so as to execute necessary treatment measures. An independent claim is included for input device for displaying necessary care or maintenance operations in framework.
Non-alcoholic steatohepatitis (NASH), caused by fat buildup, can lead to liver inflammation and damage. Elucidation of the spatial distribution of fibrotic tissue in the fatty liver in NASH can be immensely useful to understand its pathogenesis. Thus, we developed a novel serial section-3D (SS3D) technique that combines high-resolution image acquisition with 3D construction software, which enabled highly detailed analysis of the mouse liver and extraction and quantification of stained tissues. Moreover, we studied the underexplored mechanism of fibrosis progression in the fatty liver in NASH by subjecting the mice to a high-fat diet (HFD), followed by lipopolysaccharide (LPS) administration. The HFD/LPS (+) group showed extensive fibrosis compared with control; additionally, the area of these fibrotic regions in the HFD/LPS (+) group was almost double that of control using our SS3D technique. LPS administration led to an increase in Tnfα and Il1β mRNA expression and the number of macrophages in the liver. On the other hand, transforming growth factor-β1 (Tgfβ1) mRNA increased in HFD group compared to that of control group without LPS-administration. In addition, COL1A1 levels increased in hepatic stellate cell (HSC)-like XL-2 cells when treated with recombinant TGF-β1, which attenuated with recombinant latency-associated protein (rLAP). This attenuation was rescued with LPS-activated macrophages. Therefore, we demonstrated that fatty liver produced "latent-form" of TGF-β1, which activated by macrophages via inflammatory cytokines such as TNFα and IL1β, resulting in activation of HSCs leading to the production of COL1A1. Moreover, we established the effectiveness of our SS3D technique in creating 3D images of fibrotic tissue, which can be used to study other diseases as well.
Absorption: The rate and extent of absorption of mannitol after oral inhalation was generally similar to that observed after oral administration. In a study of 18 healthy adult male subjects the absolute bioavailability of mannitol powder following oral inhalation was 59% while the relative bioavailability of inhaled mannitol in comparison to orally administered mannitol was 96%. Following oral inhalation of 635 mg, the mean mannitol peak plasma concentration (Cmax) was 13.71 mcg/mL while the mean extent of systemic exposure (AUC) was 73.15 mcg•hr/mL. The mean time to peak plasma concentration (Tmax) after oral inhalation was 1.5 hour.

Distribution: Based on intravenous administration, the volume of distribution of mannitol was 34.3 L.

Elimination: Following oral inhalation, the elimination half-life of mannitol was 4.7 hours. The mean terminal elimination half-life for mannitol in plasma remained unchanged regardless of the route of administration (oral, inhalation, and intravenous). The urinary excretion rate versus time profile for mannitol was consistent for all routes of administration. The total clearance after intravenous administration was 5.1 L/hr while the renal clearance was 4.4 L/hr. Therefore, the clearance of mannitol was predominately via the kidney. Following inhalation of 635 mg of mannitol in 18 healthy subjects, about 55% of the total dose was excreted in the urine as unchanged mannitol. Following oral or intravenous administration of a 500 mg dose, the corresponding values were 54% and 87% of the dose, respectively.

Metabolism: The extent of metabolism of mannitol appears to be small. This is evident from a urinary excretion of about 87% of unchanged drug after an intravenous dose to healthy subjects.

  
Specific Populations

Patients with Hepatic and Renal Impairment: Formal pharmacokinetic studies using ARIDOL have not been conducted in patients with hepatic or renal impairment. Since the drug is eliminated primarily via the kidney, an increase in systemic exposure can be expected in renally impaired patients.
Disclosed herein are T cell receptors (TCRs) capable of binding an antigen expressed by renal cell carcinoma cells. In some examples, the TCRs include an α chain (such as SEQ ID NO: 2) and a β chain (such as SEQ ID NO: 3). Also disclosed herein are vectors including nucleic acids encoding the disclosed TCR α and/or β chains. Further disclosed are modified T cells expressing the TCRs. In some examples, the modified T cells are prepared by transducing T cells with a vector including nucleic acids encoding the TCR α chain and the TCR β chain. In some embodiments, methods include treating a subject with RCC, by obtaining a population of T cells, transducing the population of T cells with a vector including a nucleic acids encoding the TCR α chain and the TCR β chain, and administering a composition comprising the modified T cells to the subject.
The utility model relates to a sweet and crisp pilose antler chew tablet, which is used for the medicinal industry and is composed of a mixture, a pilose skin and a pilose body. The pilose body and the pilose skin are coated with mixture coating layers which make the pilose body and the pilose skin sweet and crisp. After pilose antler tablets are put in a container to be soaked in vinegar or iced vinegar, the pilose antler tablets are taken out and dried in shade. White sugar, essence, starch gum and food oil are made into the mixture, and the pilose antler tablets are put in the mixture to be mixed. The pilose antler tablets are shaped out finished products in a mould, and the pilose antler tablets are dried to sweet and crisp type. The pilose antler tablets can be chewed by a mouth after sealed and packaged. The utility model alters the defect that the existing pilose antler tablets can not be chewed by a mouth, and the application range of the utility model is wide. The manufacture process is conveniently realized, and the price is adaptable. The utility model is favorable for people's health.
Take Cnidium Monnieri Detoxification Formula orally for at least 3 months. Baseline HPV clearance, improvement in clinical symptoms and quality of life, and drug safety were assessed at 3 months, 6 months, and 12 months after initiation of treatment.